title: Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.
authors.affiliation: Vancouver General Hospital, BC, Canada ksong@bccancer.bc.ca.
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Song
authors.affiliation: Alexandra Hospital, Athens, Greece.
authors.forename: Meletios A
authors.initials: MA
authors.lastname: Dimopoulos
authors.affiliation: University Hospital Tübingen, Germany.
authors.forename: Katja C
authors.initials: KC
authors.lastname: Weisel
authors.affiliation: University Hospital Hotel-Dieu, Nantes, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.affiliation: University Hospital and Health City of Science of Torino, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
authors.affiliation: University of Alberta, Edmonton, Canada.
authors.forename: Andrew
authors.initials: A
authors.lastname: Belch
authors.affiliation: King's College Hospital and King's College London, UK.
authors.forename: Stephen
authors.initials: S
authors.lastname: Schey
authors.affiliation: Erasmus Medical Center Rotterdam, The Netherlands.
authors.forename: Pieter
authors.initials: P
authors.lastname: Sonneveld
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Lars
authors.initials: L
authors.lastname: Sternas
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Xin
authors.initials: X
authors.lastname: Yu
authors.affiliation: Adelphi Values, Boston, MA, USA.
authors.forename: Ramesh
authors.initials: R
authors.lastname: Amatya
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Mara S
authors.initials: MS
authors.lastname: Monzini
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Zaki
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Christian
authors.initials: C
authors.lastname: Jacques
authors.affiliation: Hospital Universitario de Salamanca, Salamanca, Spain.
authors.forename: Jesus
authors.initials: J
authors.lastname: San Miguel
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D003907:Dexamethasone / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D011788:Quality of Life; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D013792:Thalidomide; D003907:Dexamethasone; C467566:pomalidomide
keywords: Pomalidomide; multiple myeloma; quality of life